Plain-English translation of NCT05758610 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can safely and effectively treat two types of blood cancers—acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL)—in patients whose cancer has returned or stopped responding to standard treatments. Researchers will gradually test different doses of this medication to find the safest and most effective dose. The medication is taken as a tablet once daily.
Many patients with relapsed or refractory AML and NHL have limited treatment options left after standard therapies fail. This trial exists to find a new, effective treatment option for these patients and to understand how safe this medication is at different dose levels.
You will take this medication as a tablet by mouth once every day for 28-day treatment cycles. The trial has two parts: first, researchers will gradually increase the dose in small groups of patients to find the safest dose level; then, more patients will be treated at that recommended dose. Throughout the trial, you will have regular visits with the study team for blood work, physical exams, and check-ins to monitor how you are responding and watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shengke Pharmaceuticals (Jiangsu) Limited, China
Enrollment target
~60 participants
Started
November 2022
Primary completion
December 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
James Zhang, Master
Shengke Pharmaceuticals (Jiangsu) Limited, China